Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks oldstocks. Nice find!
Still agreeing with you on this one.
I agree. I feel better with rspi than the rgb. P
Same here
Thanks Zino! Glty
Thanks fly! Appreciate the info. Dumped my screenshot of rgbp a while back. Was figuring rgbp had 6x the amount of shares.
Was there for that one.
If I remember correctly Rspi has a "better" share structure than regen.
Looking forward to the possibilities here.
Yeet! :)
Agreed. All we need is Taps to play, though propanc is Australian.
Crickets, lol
Yw Zim
We intend to
seek and identify potential licensees based on the
initial efficacy data from Phase II clinical trials. To accomplish this objective, we have
commenced discussions with potential partners
in our current preclinical phase of development.
Just some interesting stuff from POS.... Propanc Biopharma is collaborating
with
contract research organizations, manufacturing
partners and consultants to complete activities
prior to preparing the CTA for the Phase Tb study.
Welcome Mutat. Only seen you and another here from rgb..p
Thanks Jack
Can I hold you to your word?
Promise?
IKR? Noticed that too
From otc market website regarding onph mentioning rgbp.
2. Current status as a non-shell company: I am of the opinion that ONPH is not currently a
shell company based upon the following:
a. The 2022 Annual Reports reveal that ONPH is engaged in the business of licensing,
developing, manufacturing and commercializing therapeutics.
b. ONPH, per an agreement with Sybleu Therapeutics, has been granted an exclusive world?wide license to develop its cancer therapy. ONPH has also been granted a license by
NanoSmart Pharmaceuticals Inc. for its "novel" drug delivery platform targeting many
types of cancer and other diseases. ONPH has also been granted a license by KCL
Therapeutics Inc., a wholly owned subsidiary of Regen Biopharma to develop a treatment
for human colon cancer; and a license with Ribera Solutions to develop its clinical trial
patient retention app.
c. ONPH is currently engaged in an active trade or business.
d. For the fiscal year ended March 31, 2022 Annual report, cash constitutes less than 2.5%
of total assets.
e. For the fiscal year ended March 31, 2022, ONPH reported operating expenses (exclusive
of depreciation expense) of $61,201.00. ONPH also made investments in licensing
agreements with NanoSmart Pharmaceuticals for $351,350, KCL Therapeutics for
$1,400,000; Regen Biopharma $55,000; and Ribera Solutions $75,000. These operations
and investments demonstrate greater than nominal operations for a company in this stage
of development. The financial statements of ONPH are consistent with an operating
business.
Thanks thug
Looked yesterday, there was nothing, only mention with Rgbp. Googled this am and there is much more info than yesterday.
Yeah and who is Coventry? About as much info on them as Canary.
And a huge difference in outstanding shares
Right!?
I've seen too many people not understand market cap when comparing rgbp to others.
Just found this. Havent read..... https://www.sec.gov/edgar/browse/?CIK=1818674
I hope we are holding aces!
Nice find.
EGEN BIOPHARMA, INC.: MESSAGE TO THE SHAREHOLDERS FROM THE CHAIRMAN AND CHIEF EXECUTIVE OFFICER
SAN DIEGO, Dec. 30, 2021 /PRNewswire/ -- Regen BioPharma, Inc. (PINK: RGBP) and (PINK: RGBPP):
First of all I would like to wish all our shareholders a happy holiday season. It has been a long year with many challenges and many successes.
When I returned to Regen on March 23, 2021 in order to serve as Chairman and Chief Executive Officer I found myself at the helm of a company on the verge of collapse. We were behind in bills, at risk of losing patent protection on valuable IP, and delinquent in our SEC filing obligations. Worse of all we were being sued by Chemdiv-our Contract Research Organization- in a complaint seeking damages of $1,200,000 which also threatened our ownership rights to valuable intellectual property
As the year progressed we faced the challenges that lay before us and conquered them. Regen has revived numerous valuable existing IP which had been deemed abandoned by the United States Patent and Trademark Office, settled its lawsuit with Chemdiv, been issued several new patents, entered into two non-related party licensing agreements and became current in its SEC filing obligations eliminating the risk that the public trading market for both the common and Series A preferred shares would disappear.
Becoming current in our SEC reporting obligations after such a long delinquency was a significant achievement. Recent amendments to SEC Rule 15c2-11 threatened the public trading status of delinquent issuers. Had I not been able to get the Company current there was a real possibility that our shareholders wouldn't be able to trade their shares and the Company's ability to raise capital would be adversely effected.
I have received numerous texts, emails and phone calls regarding our restatement of our third quarter financials.
During the quarter ended June 30, 2021 the Company was paid $1,905,000 in cash and securities resulting from two licenses granted in April, 2021 to Oncology Pharma, Inc. ("ONPH").
Pursuant to the terms and conditions of the licenses granted ONPH became obligated to:
(a) Pay nonrefundable fees of $55,000 and fifty thousand common shares of ONPH no later than April 20, 2021
(b) Pay royalties equal to five percent (5%) of the Net Sales (as Net Sales are defined in the Agreement) of any Licensed Products in a quarter.
Accounting for Revenues from contracts with customers and licensees is governed by Accounting Standard Codification 606 ("ASC 606") issued by the Financial Accounting Standards Board ("FASB").
ASC 606 requires that revenue be recognized as performance obligations are fulfilled. In considering the accounting for revenue generated by the licenses, the Company initially determined that the nonrefundable fees paid were consideration solely for entering into the agreement and thus should be recognized within the quarter in which they were paid.
A subsequent examination in conjunction with the Company's public accountant led us to reconsider this accounting treatment and we determined that -- in order to be compliant with ASC 606- the revenue generated by the payment to the Company of the nonrefundable fees would need to be recognized over the term of the licenses. We arrived at the conclusion that entering into the agreement did not adequately meet the criteria of being "distinct within the context of the contract" from the obligation of granting the license over the term of the contract. None of the abovementioned changes the fact that $1,905,000 in cash and securities was paid to the Company during the quarter ended June 30, 2021 and this payment was nonrefundable.
Looking into the New Year I will work diligently towards the goal of entering into additional co-development projects and collaborations that I believe will benefit Regen's shareholders and I expect to identify a contract research organization that will help us move the Company's intellectual propriety towards clinical trials.
During this past year I haven't taken a dime in salary from Regen. The reason for this is because I see our company for all its potential and possibilities and I'm betting on what we have and what we can achieve.
Sincerely,
David R. Koos
Chairman & CEO
Regen BioPharma Inc.
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-722-5505 Phone
+1-619-330-2328 Fax
david.koos@regenbiopharma.com
http://www.regenbiopharmainc.com
View original content:https://www.prnewswire.com/news-releases/regen-biopharma-inc-message-to-the-shareholders-from-the-chairman-and-chief-executive-officer-301452028.html
SOURCE Regen BioPharma, Inc.
(END) Dow Jones Newswires
December 30, 2021 15:41 ET (20:41 GMT)
For those that don't know.....
https://samsungbiologics.com/
Yeah something like 300 billion to invest over next ten years or so. Numbers may not be exact but they got dough to spend
Wonder if this means their(Ichim and Patel) focus is on rgbp more.
https://ih.advfn.com/stock-market/NASDAQ/creative-medical-technol-CELZ/stock-news/86750370/current-report-filing-8-k
You thinking we'll close on the VWAP? Seems to be routine.
I agree with you. I was in Celz believing in the potential and the product, before the split announcement. Am glad I am out . If you have thousands of shares left or got in with thousands you'll be good, if not, eh.